Lv31
310 积分 2023-06-03 加入
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning—the IG-IBD LIVE study
1小时前
已完结
Gut immune cell trafficking: inter-organ communication and immune-mediated inflammation
22小时前
已完结
Interleukin-23: A key cytokine in inflammatory diseases
9天前
已完结
Interleukin-23 biology linking mucosal immunity to autoimmune diseases and cancer
16天前
已完结
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
1个月前
已完结
Unmet needs in inflammatory bowel disease
1个月前
已完结
Inflammatory Bowel Disease
1个月前
已完结
Inflammatory Bowel Disease
1个月前
已完结
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
1个月前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
1个月前
已完结
皖公网安备34019202002308
